Charles River Laboratories International (CRL) to Release Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of $2.51 per share for the quarter. Persons that are interested in participating in the company's conference call can do so using this link.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business's revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.72 EPS. On average, analysts expect Charles River Laboratories International to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Charles River Laboratories International Stock Down 1.6 %

CRL traded down $2.62 during trading on Friday, hitting $163.65. The company had a trading volume of 564,421 shares, compared to its average volume of 1,002,698. The company has a market cap of $8.37 billion, a PE ratio of 20.48, a P/E/G ratio of 6.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International has a 1-year low of $159.65 and a 1-year high of $275.00. The business has a 50-day moving average of $180.61 and a 200-day moving average of $193.44.

Analyst Ratings Changes

A number of equities analysts recently commented on CRL shares. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. CLSA downgraded shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective for the company. in a research report on Monday, November 18th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a "sell" rating and a $151.00 target price on the stock. Finally, TD Cowen upped their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, Charles River Laboratories International currently has an average rating of "Hold" and a consensus target price of $200.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).